Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM0306 (Amurifup alpha) plus lenalidomide vs placebo plus lenalidomide in relapsed/refractory follicular lymphoma
CTR20254707Phase 3Active
- Sponsor
- ImmuneOnco
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) comparing IMM0306 + lenalidomide with Placebo + lenalidomide (2 arms). Primary endpoints: Complete response rate (CRR) by investigator assessment and Progression-free survival (PFS) by investigator assessment. Started Mar 2026; status: active.
02
Drugs
IMM0306S
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20254707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254707.